NCT00864786View on ClinicalTrials.gov

Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

PF03635659

Inhaled doses of 200 mcgQD

DRUG

PF03635659

Inhaled doses of 600 mcg QD

DRUG

PF03635659

Inhaled doses of 1000 mcg QD

DRUG

PF03635659

Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.

DRUG

PF03635659

Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00864786 - Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study | Biotech Hunter | Biotech Hunter